Hematology
PHASE2
● Phase II
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment
ClinicalTrials.gov
Published March 30, 2026
Dana-Farber Cancer Institute
NCT02135133 ↗
This was a phase 2 interventional clinical trial involving 27 participants diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who had not received prior treatment but required therapy. The intervention studied was the combination of idelalisib and ofatumumab. No comparator group was reported. The primary outcome measure was overall response rate, with a median follow-up of 76.2 months. No specific efficacy results for this trial were provided in the available data.
Regarding safety and tolerability, no specific adverse event, serious adverse event, or discontinuation rates were reported for this study. The text notes that this drug combination has been previously tested and appeared to be well tolerated, but this is not data from the current trial.
Key limitations include the small sample size of 27 patients, the lack of reported efficacy results, and the absence of a comparator group. The phase 2 design and single-arm nature provide preliminary evidence only. Funding sources and conflicts of interest were not reported.
For clinical practice, this report describes an early-phase trial exploring a combination regimen. Without reported efficacy outcomes, no conclusions about treatment benefit can be drawn. The tolerability comment is based on prior testing, not this specific trial. Clinicians should await peer-reviewed publication of complete results before considering any clinical implications.
When you're diagnosed with a blood cancer like chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and your doctor says you need treatment, the search begins for an option that works well and feels manageable. A recent study explored whether using two drugs together—idelalisib and ofatumumab—could be a potential path for people who haven't had any prior treatment.
The trial followed 27 patients for over six years. While the specific results on how well the treatment worked weren't reported in the available information, the combination of these two drugs had been tested before and appeared to be well tolerated. This means patients in earlier studies generally handled the treatment without severe issues, which is an important consideration for quality of life.
It's crucial to understand this was a phase 2 trial, which is an early step in testing new treatment approaches. These studies are designed to gather initial information, not to provide definitive answers. We don't yet have the key findings on whether this drug combination effectively treats CLL or SLL. More research would be needed to determine if this approach could become a standard option for patients.
What this means for you: Early trial tests two-drug combo for untreated blood cancer; efficacy results pending.
View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Intervention(s): Idelalisib (DRUG), Ofatumumab (DRUG)
This research study is evaluating a combination of drugs called Ofatumumab and Idelalisib as a possible treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL).
The main purpose of this study is to examine the combination of the two drugs, Ofatumumab and Idelalisib, in participants who have been diagnosed with CLL/SLL and have not previously received treatment but do require treatment. The investigators hope to observe how participants' disease will be impacted by this treatment and whether they will benefit more from combining these drugs together rather than taking them separately. Both of these drugs have been used in treatment for CLL / SLL and information from those research studies suggests that these drugs may help patients with CLL/SLL.
Ofatumumab is an antibody engineered in the lab against CD20, a protein on the surface of CLL cells, which is expressed in CLL. An antibody is a molecule your body creates to identify foreign substances so that it can destroy them. Ofatumumab has been FDA approved for treatment of CLL/SLL that has relapsed or progressed on other therapies. Idelalisib is a drug that blocks one of the signals inside the cells that cause this type of cancer to grow and survive. The investigators hope that combining Ofatumumab with Idelalisib will stop the growth of disease.
In this research study, the investigators are evaluating the side effects of combining these two drugs, gathering information on the CLL/SLL disease process and how the study affects the patient's cells, as well as assessing the outcome of the disease. This combination of drugs has been previously tested, and appeared to be well tolerated.
Detailed: Before the research starts (screening): After signing the consent form, the participant will be asked to undergo some screening tests or procedures to find out if they are eligible to be in this research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that the participant does not take part in the research study. If the participant has had some of these tests or procedures recently, they may or may not have to be repeated.
* A medical history, which includes questions about the participant's health, current medications, and any allergies.
* Physical examination, which includes vital signs, height, weight, and disease assessment by the size of the participant's spleen, liver, and lymph nodes.
* Performance status,
Primary Outcome(s): Overall Response Rate (ORR)
Enrollment: 27 (ACTUAL)
Lead Sponsor: Dana-Farber Cancer Institute
Start: 2014-06 | Primary Completion: 2020-10-06
Results posted: 2024-10-16
